Winston Pharmaceuticals, Inc., a Vernon Hills, IL-based specialty pharmaceutical company focused on developing and commercializing novel pain management therapies, has received a $375k grant from the National Institutes of Health (NIH) under the Small Business Innovation Research (SBIR) program.
The company intends to use the funding to develop Civamide, a proprietary TRPV-1 receptor modulator, for the treatment of postherpetic neuralgia (PHN) of the trigeminal nerve (TN). The Phase I award will be administered by the National Institute of Neurological Disorders and Stroke (NINDS).
Led by Joel E. Bernstein, M.D., President and CEO, Winston is a pharmaceutical company focused on developing pain management products for large pain-control markets, as well as on niche markets. The company’s late-stage product candidates span a range of pain indications, including episodic cluster headache, migraine and tension headache, osteo- and rheumatoid arthritis, neuropathic pain, cancer pain and pain associated with inflammatory bowel disease.